Trandolapril. An update of its pharmacology and therapeutic use in cardiovascular disorders

Drugs

Volumn 56, Issue 5, 1998, Pages 871-893

  Peters, Dene C ^a   Noble, Stuart ^a   Plosker, Greg L ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; TRANDOLAPRIL; VERAPAMIL;

ASTHENIA; BLOOD PRESSURE REGULATION; CARBOHYDRATE METABOLISM; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; COUGHING; DRUG EFFICACY; HEADACHE; HEART INFARCTION; HEART LEFT VENTRICLE FAILURE; HUMAN; HYPERTENSION; LIPID METABOLISM; META ANALYSIS; MORTALITY; NAUSEA; REVIEW; SUSTAINED RELEASE FORMULATION; VERTIGO;

EID: 0031767184     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-199856050-00014     Document Type: Review

References (98)

1. Wiseman LR, McTavish D. Trandolapril: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in essential hypertension. Drugs 1994 Jul; 48: 71-90
2. Weir MR, Gray JM, Paster R, et al. Differing mechanisms of action of angiotensin-converting enzyme inhibition in black and while hypertensive patients. Hypertension 1995 Jul; 26: 124-30
3. Arner P, Wade A, Engfeldt P, et al. Pharmacokinetics and pharmacodynamics of trandolapril after repeated administration of 2mg to young and elderly patients with mild-to-moderate hypertension. J Cardiovasc Pharmacol 1994; 23 Suppl. 4: S44-9
4. Bouvier D'Yvoire M, Caplain H, Stepniewski J-P. Comparison of plasma ACE activity after discontinuation of repeated doses of trandolapril or ervalapril [abstract]. Am J Hypertens 1994 Apr; 7 (Pt 2): 35A
5. Vicaut E, Hou X. Duration of inhibtion of local microvascular ACE in spontaneously hypertensive rats. J Hypertens 1995 Dec; 13 (Pt 2): 1758-63
6. Sanbe A, Tsukada J, Takeo S. Effects of trandolapril on cardiac angiotensin I converting enzyme activity in rats with chronic heart failure following myocardial infarction. Jpn Heart J 1995: 451-63
7. Schroeder R-J, Cordes M, Del N, et al. Left ventricular hypertrophy regression under therapy with ACE-inhibitors: a comparison of four substances. Perfusion 1994 Mar; 7: 82-90
8. Predel HG, Rohden C, Schramm T, et al. Effects of various antihypertensive treatment regimens on systemic haemodynamics, energy metabolism and physical performance in physically active patients with essential hypertension [abstract]. Int J Sports Med 1996 Apr; 17 Suppl. 1: S12
9. van den Heuvel AFM, van der Ent M, Remme WJ. Acute haemodynamic and antiischaemic effects of trandolapril in patients with coronary artery disease. Is the cardiac renin-angiotensin system involved? [abstract no. 1067]. Eur Heart J 1997 Aug; 18 Abstract Suppl.: 170
10. Bugra Z., Mercanoglu F, Vural A, et al. Short-term effects of the long-acting angiotensin converting enzyme inhibitor trandolapril on left ventricular diastolic filling indexes in hypertensive patients [abstract]. Am J Hypertens 1997 Apr; 10 (Pt 2); 134
11. Lazareva IV, Liventseva MM, Nechesova TA. Long-term monotherapy with trandolapril in hypertensive patients with left ventricular hypertrophy [abstract]. J Hypertens 1997 Jun; 15 Suppl. 4: S158
12. Cesarone MR, Belcaro G, Incandela L, et al. Mild to moderate essential hypertension treated with trandolapril: improvements in circulation and microcirculation. Adv Ther 1997 Mar-Apr; 14: 73-88
13. Chevalier B, Heudes D, Heymes C, et al. Trandolapril decreases prevalence of ventricular ectopic activity in middle-aged SHR. Circulation 1995 Oct 1; 92: 1947-53
14. Chevalier B, Medigue C, Heymes C, et al. Trandolapril improves the heart rate variability in middle-aged spontaneously hypertensive rats [abstract]. Eur Heart J 1996 Aug; 17 Abstract Suppl.: 9
15. 2+ antagonist verapamil [abstract]. Eur Heart J 1995 Aug; 16 Suppl.: 171
16. Muller CA, Opie LH, Peisach M, et al. Chronic oral pretreatment with the angiotensin converting enzyme inhibitor, trandolapril decreases ventricular fibrillation in acute ischaemia and reperfusion. Eur Heart J 1994 Jul; 15: 988-96
17. Boraso A, Ceconi C, Cargnoni A, et al. Blockade of β-adrenoceptor desensitisation following treatment with the ACE-inhibitor trandolapril [abstract]. Eur Heart J 1997 Aug; 18 Abstract Suppl.: 159
18. Sanbe A, Takeo S. Long-term treatment with angiotensin I-converting enzyme inhibitors attenuates the loss of cardiac β-adrenoceptor responses in rats with chronic heart failure. Circulation 1995 Nov 1; 95: 2666-75
19. Sanbe A, Tanonaka K, Kobayasi R, et al. Effects of long-term therapy with ACE inhibitors, captopril, enalapril and trandolapril, on myocardial energy metabolism in rats with heart failure following myocardial infarction. J Mol Cell Cardiol 1995 Oct; 27: 2209-22
20. Yamaguchi F, Sanbe A, Takeo S. Effects of long-term treatment with trandolapril on sarcoplasmic reticulum function of cardiac muscle in rats with chronic heart failure following myocardial infarction. Br J Pharmacol 1998 Jan; 123: 326-34
21. Muller CA, Opie LH, Pineda CA, et al. Combination of a calcium antagonist verapamil with an angiotensin converting enzyme inhibitor, trandolapril in experimental myocardial ischemia and reperfusion. Cardiovasc Drugs Ther In press
22. Bauduceau B, Vaur L, Rezvani Y, et al. Action of trandolapril on the blood glucose balance and microalbuminuria in hypertensive diabetics [in French]. Ann Cardiol Angeiol 1994 Feb; 43: 84-8
23. Petrie JR, Morris AD, Ueda S, et al. Trandolapril does not affect insulin sensitivity in patients with essential hyertension and impaired glucose tolerance/NIDDM [abstract]. J Hypertens 1997 Dec; 15 Pt 1: 1541
24. Sigurdsson A, Andersson G, Hall C, et al. Neurohormonal effects of trandolapril in patients with a recent onset acute myocardial infarction and reduced left ventricular function [abstract]. Eur Heart J 1996 Aug; 17 Abstract Suppl.: 62
25. van der Ent M, van den Heuvel AFM, Bartels LG, et al. Preservation of renal function in patients with severe heart failure in long-term treatment with trandalopril [abstract]. 1st Int Meet Work Group Heart Fail 1995 Apr 1: 53
26. Adalet K, Büyüköztürk K, TMTS G. Trandolapril in overweight patients with mild-to-moderate essential hypertension: the Turkish Multicenter Trandolapril Study. Curr Ther Res Clin Exp 1996 Dec; 57: 980-9
27. Aranda P, Aranda FJ, Frutos M, et al. Amlodipine versus trandolapril in type 2 diabetic essential hypertensives: a long-term comparison study [abstract]. Am J Hypertens 1996 Apr; 9 (Pt 2): 143A
28. Reneland R, Alvarez E, Andersson P-E, et al. Insulin resistance during atenolol treatment: a parallel group comparison with trandolapril [abstract]. J Hypertens 1996 Jun; 14 Suppl. 1: S229
29. Galletti F, Capaldo B, Carretta R, et al. Effects of trandolapril and nifedipine-GITS on whole body and skeletal muscle insulin sensitivity in overweight hypertensives [abstract no. E026]. Am J Hypertens 1998; 11 (4 Pt 2): 102A
30. Lenfant B, Mouren M, Bryce T, et al. Trandolapril: pharmacokinetics of single oral doses in healthy male volunteers. J Cardiovasc Pharmacol 1994; 23 Suppl. 4: S38-43
31. Danielson B, Querin S, LaRochelle P, et al. Pharmacokinetics and pharmacodynamics of trandolapril after repeated administration of 2 mg to patients with chronic renal failure and healthy control subjects. J Cardiovasc Pharmacol 1994; 23 Suppl. 4: S50-59
32. Chevillard C, Jouquey S, Mathieu M-N, et al. Passage of blood brain barrier by trandolapril and enalapril in SH rats after chronic treatment [abstract]. Pharmacol Res 1995; 31 Suppl.: 322
33. Saunders R, editor. New Ethicals Compendium. 6th ed. Auckland: Adis International Ltd., 1997
34. Meyer BH, Müller FO, Badenhorst PN, et al. Multiple doses of trandolapril do not affect warfarin pharmacodynamics. S Afr Med J 1995 Aug; 85: 768-70
35. Pauly NC, Safar ME, Investigator Study Group. Comparison of the efficacy and safety of trandolapril and captopril for 16 weeks in mild-to-moderate essential hypertension. J Cardiovasc Pharmacol 1994; 23 Suppl. 4: S73-6
36. Arakawa K, Saruta T, Iimura O, et al. Clinical evaluation of angiotensin converting enzyme inhibitor, trandolapril (RU 44750) in patients with essential hypertension - multi-centered double-blind comparative study in comparison with enalapril maleate [in Japanese]. Rinsho Hyoka 1992 Nov; 20: 477-511
37. de Leeuw PW, Pauly NC. Double-blind comparison of efficacy and safety of trandolapril 4 mg and enalapril 20 mg in patients with mild to moderate hypertension [abstract]. J Hypertens 1992 Jun; 10 Suppl. 4: 199
38. Poirier L, Bourgeois J, Lefebvre J, et al. ACE inhibitors as first-line treatment agents: a comparative study of trandolapril and enalapril on casual and ambulatory blood pressures. Am J Ther 1995 Mar; 2: 159-64
39. Vaur L, Dutrey-Dupagne C, Boussac J, et al. Differential effects of a missed dose of trandolapril and enalapril on blood pressure control in hypertensive patients. J Cardiovasc Pharmacol 1995 Jul; 26: 127-31
40. Vaur L, Bobrie G, Dutrey-Dupagne C, et al. Short-term effects of w ithdrawing angiotensin converting enzyme inhibitor therapy on home self-measured blood pressure in hypertensive patients. Am J Hypertens 1998 Feb; 11 (2): 165-73
41. Zannad F, Vaur L, Dutrey-Dupagne C. Antihypertensive effects of trandolapril and nitrendipine in the elderly: a controlled trial with special emphasis on time effect profiles. J Hum Hypertens 1996 Jan; 10: 51-5
42. Meyer BH, Pauly NC, Investigator Study Group Double-blind comparison of the efficacy and safety of trandolapril 2mg and hydrochlorothiazide 25mg in patients with mild-to-moderate essential hypertension. J Cardiovasc Pharmacol 1994; 23 Suppl. 4: S77-80
43. Winnicki M, Sobiczewski W, Bartlomiejczyk-Majchrowicz K, et al. Effects of the once-a-day amlodipine and trandolapril on 24-hour ambulatory blood pressure and its short-term variability [abstract]. Am J Hypertens 1996 Apn 9 (Pt 2): 153A
44. Steiner G, Pauly NC, Investigator Study Group. Comparison of the efficacy and safety of trandolapril and nifedipine SR in mild-to-moderate hypertension. J Cardiovasc Pharmacol 1994; 23 Suppl. 4: S81-5
45. Compagnone D, Zilles D. Multifactorial study to establish the antihypertensive efficacy of trandolapril in combination with verapamil SR [abstract]. 7th European Meeting on Hypertension 1995 Jun 9: 41-2
46. Levine JH, Applegate WB, Trandolapril Verapamil Study Group. Trandolapril and verapamil slow release in the treatment of hypertension: a dose-response assessment with the use of a multifactorial trial design. Curr Ther Res Clin Exp 1997 Jun; 58: 361-74
47. Messerli F, Frishman WH, Elliott WJ, et al. Effects of verapamil and trandolapril in the treatment of hypertension. Am J Hypertens 1998; 11: 322-7
48. Nalbantgil I, Önder R, Nalbantgil S. Sustained-release verapamil and trandolapril, alone and in combination, in the treatment of ohese hypertensive patients: a double-blind pilot study. Curr Ther Res Clin Exp 1996 Dec; 57: 990-7
49. Veratran Study Group. Effects of verapamil SR, trandolapril, and their fixed combination on 24-h blood pressure. Am J Hypertens 1997; 10: 492-9
50. Viskoper JR, Dies R, Zilles P. Verapamil SR 180mg, trandolapril 2 mg and the fixed combination thereof for the treatment of moderate essential hypertension [abstract]. Am J Hypertens 1996 Apr: 9 (Pt 2): 140A
51. Gaillard CA, de Leeuw PW. Clinical experiences with trandolapril. Am Heart J 1993; 125 (5 Pt 2): 1542-6
52. Backhouse CI, Orofiamma B, Pauly NC. Long-term therapy with trandolapril, a new nonsulfhydryl ACE inhibitor, in hypertension: a multicenter international trial. J Cardiovasc Pharmacol 1994; 23 Suppl. 4: S86-90
53. Punzi HA, Novrit BA. The treatment of severe hypertension with trandolapril, verapamil, and hydrochlorothiazide. Trandolapril/Verapamil Multicenter Study Group [see comments]. J Hum Hypertens 1997 Aug; 11: 477-81
54. Morgan T, Anderson A. How important is 24-hour control of blood pressure? Drug Saf 1996 Oct; 15: 243-8
55. Meredith PA. Importance of trough: peak ratios in treatment of blood pressure in post-myocardial infarction and heart failure settings. J Hum Hypertens 1997 Jan; 11: 39-43
56. Joint National Committee. The Sixth Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med 1997 Nov 24; 157: 2413-46
57. Zannad F, Matzinger A, Larche J. Trough/peak ratios of once daily angiotensin converting enzyme inhibitors and calcium antagonists. Am J Hypertens 1996 Jul; 9: 633-43
58. Zannad F, Genès N, Vaur L, et al. Time-effect profile of long acting ACE inhibitors: comparison of the trough to peak ratios of enalapril, lisinopril and trandolapril [abstract]. 7th European Meeting on Hypertension 1995 Jun 9: 210
59. Cesarone MR, De Sanctis MT, Laurora G, et al. Effects of trandolapril on 24-H ambulatory blood pressure in patients with mild-to-moderate essential hypertension. J Cardiovasc Pharmacol 1994; 23 Suppl. 4: S65-72
60. Omboni S, Ravogli A, Villani A, et al. Permanent blood pressure control over the 24 h by trandolapril. Am J Hypertens 1995 Oct; 8 (Pt 2): 71S-4S
61. Smith DHG, Neutel JM, Black HR, et al. Once-daily monotherapy with trandolapril in the treatment of hypertension. J Hum Hypertens 1996 Feb; 10: 129-34
62. Kownator S, Dutrey-Dupagne C, Vaur L, et al. Evaluation of the duration of action of trandolapril by ambulatory blood pressure monitoring [in French]. Therapie 1994 Mar-Apr; 49: 89-93
63. Gosse P, Vaur L, Dutrey-Dupagne C, et al. Evaluation of trandolapril alone or in combination with a calcium channel blocker in hypertensive patients over 60 years old [in French]. Ann Cardiol Angeiol 1995 Nov; 44: 517-24
64. Maarek M, Bensaïd J. Efficacy and safety of trandolapril in over weight hypertensive patients [in French]. Ann Cardiol Angeiol 1996 Jun; 45: 343-51
65. Kober L, Torp-Pedersen C, Carlsen JE, et al. A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 1995 Dec 21; 333: 1670-6
66. Trace Study Group. The TRAndolapril Cardiac Evaluation (TRACE) Study: rationale, design, and baseline characteristics of the screened population. Am J Cardiol 1944 Apr 7; 73: 44C-50C
67. Kober L, Torp-Pedersen C, Carlsen J, et al. An echocardiographic method for selecting high risk patients shortly after acute myocardial infarction, for inclusion in multi-centre studies (as used in the TRACK study). Eur Heart J 1994 Dec; 15: 1616-20
68. Kober L, Torp-Pedersen C, Pedersen OD, et al. Importance of congestive heart failure and interaction of congestive heart failure and left ventricular systolic function on prognosis in patients with acute myocardial infarction. Am J Cardiol 1996 Nov 15; 78: 1124-8
69. Gustafsson F, Torp-Pedersen C, Kober E, et al. Effect of angiotensin converting enzyme inhibition after acute myocardial infarction in patients with arterial hypertension. TRACE Study Group, Trandolapril Cardiac Event. J Hypertens 1997 Jul; 15: 793-8
70. LePen C, Lilliu H, Keller T, et al. The economics of TRACE: a cost effectiveness analysis of trandolapril in postinfarction patients with left ventricular dysfunction. PharmacoEconomics 1998 Jul; 14 (1): 49-58
71. Le Pen C, Bracard I. Medico-economic assessment of ACE inhibitors after myocardial infarction. J Am Coll Cardiol 1998 Apr; 31 Suppl.C: 80C
72. Konstam MA, Dracup K, Bottorff MB, et al., editors. Heart failure: evaulation and care of patients with left-ventricular systolic dysfunction. AHCPR Publication no:94-0612: Clinical Practice Guideline no. 11 ed. Rockville (MA): US Dept of Health & Human Services, 1994
73. Task Force of the Working Group on Heart Failure of the European Society of Cardiology. The treatment of heart failure. Eur Heart J 1997 May; 18: 736-53
74. Sugimoto T, Iizuka M, Hayakawa K, et al. Effect of trandolapril on chronic heart failure - early phase II study [in Japanese]. Rinsho Iyako 1997; 13 (17): 4353-72
75. Hansen JF, Hagerup L, Sigurd B, et al. Treatment with verapamil and trandolapril in patients with congestive heart failure and angina pectoris or myocardial infarction. Am Heart J 1997 Aug; 134 (Pt 2): 48-52
76. Jouglard J, Hamel J-D, Juvin P. A pharmacoepidemiologic study of trandolapril. Curr Ther Res Clin Exp 1997 Sep; 58: 555-63
77. Knoll AG, Prescribing Information MAVIK® (trandolapril). Mount Olive, New Jersey, 1997
78. Korzeniowska K, Oko-Sarnowska Z, Jablecka A, et al. The cough as adverse effects of different angiotensin-converting enzymes (ACE) inhibitors (abstract). Eur J Clin Pharmacol 1997; 52 Suppl.: A95
79. Knoll AG. A way forward in cardiovascular therapy: Gopten® (trandolapril). Ludwigshafen: Knoll AG, 1996
80. Pritchard G, Lyons D, Webster J, et al. Indomethacin does not attenuate the hypotensive effect of trandolapril. J Hum Hypertens 1996 Nov; 10: 763-7
81. Shionoiri H. Pharmacokinetic drug interactions with ACE inhibitors. Clin Pharmacokinet 1993; 25 (1): 20-58
82. Joint National Committee. The Fifth Report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure (JNC V). Arch Intern Med 1993 Jan 25; 153: 154-83
83. Guidelines Sub-Committee. 1993 guidelines for the management of mild hypertension: memorandum from a World Health Organization/International Society of Hypertension meeting. J Hypertens 1993; 11: 905-18
84. Hoyer J, Schultze K-L, Lenz T. Clinical pharmacokinetics of angiotensin converting enzyme (ACE) inhibitors in renal function. Clin Pharmacokinet 1993 Mar; 24 (3): 230-54
85. Wagstaff AJ, Davis R, McTavish D. Fosinopril: a reappraisal of its pharmacology and therapeutic efficacy in essential hypertension. Drugs 1996 May; 51: 777-91
86. Swedberg K, Sharpe N. The value of angiotensin converting enzyme inhibitors for the treatment of patients with left ventricular dysfunction, heart failure or after acute myocardial infarction. Eur Heart J 1996 Sep; 17: 1306-11
87. Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet 1993 Oct 2; 342: 821-8
88. Kingma JH, van Gilst WH, Peels CH, et al. Acute intervention with captopril during thrombolysis in patients with first anterior myocardial infarction: results from the Captopril and Thrombolysis Study (CATS). Eur Heart J 1994; 15: 898-907
89. Chinese Cardiac Study Collaborative Group. Oral captopril versus placebo among 13 634 patients with suspected acute myocardial infarction: interim report from the Chinese Cardiac Study (CCS-I). Lancet 1995 Mar 18; 345: 686-7
90. Swedberg K, Held P, Kjekshus J, et al. Effects of the early administration of enalapril on mortality in patients with acute myocardial infarction: results of the Cooperative New Scandinavian Enalapril Survival Study II (CONSENSUS II). N Engl J Med 1992 Sep 3; 327 (10): 678-84
91. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico. GISSI-3: effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction. Lancet 1994 May 7; 343: 1115-22
92. ISIS-4 (Fourth International Study of Infarct Survival) Collaborative Group. ISIS-4: a randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58 050 patients with suspected acute myocardial infarction. Lancet 1995 Mar 18; 345: 669-85
93. Pfeffer MA, Braunwald E, Moye LA, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the Survival and Ventricular Enlargement trial. N Engl J Med 1992 Sept 3; 327 (10): 669-77
94. Ambrosioni E, Borghi C, Magnani B, et al. The effect of the angiotensin-converting-enzyme inhibitor zofenopril on mortality and morbidity after anterior myocardial infarction. N Engl J Med 1995 Jan 12; 332 (2): 80-5
95. ACE Inhibitor Myocardial Infarction Collaborative Group. Indications for ACE inhibitors in the early treatment of acute myocardial infarction: systematic overview of individual data from 100 000 patients in randomized trials. Circulation 1998; 97: 2202-12
96. Pfeffer MA. ACE inhibitor in acute myocardial infarction: patient selection and timing. Circulation 1998 Jun 9; 97: 2192-4
97. Pfeffer MA, Domanski M, Rosenberg Y, et al. Prevention of events with angiotensin converting enzyme inhibition: the PEACE study design. Am J Cardiol 1998 Aug 6; 82 Suppl.: 25H-30H
98. Pepine CJ. Ongoing clinical trials of angiotensin-converting enzyme inhibitors for treatment of coronary artery disease in patients with preserved left ventricular function. J Am Coll Cardiol 1996 Apr; 27 (5): 1048-52